Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine A Phillips

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Neuropsychiatric Disease and Treatment|August 8, 2019
Reduction in apathy following epilepsy surgeryLinda Mah, Joan Swearer, Catherine A Phillips, et al.
Immunopharmacology and Immunotoxicology|May 18, 2010
Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutionsStephen E Wright, Imelda S Quinlin, Kathleen A Rewers-Felkins, et al.
Immunological Investigations|June 15, 2007
MHC-restricted presentation of a single repeat of MUC1 mucinMelody K Orr, Janet S Burnside, Catherine A Phillips, et al.
Immunological Investigations|April 5, 2008
MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cellsStephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Clinical Immunology (Orlando, Fla.)|September 19, 2009
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survivalMark J Dobrzanski, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
International Journal of Molecular Medicine|March 14, 2002
Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cellsStephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Cancer Immunology, Immunotherapy : CII|November 16, 2011
Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancerMark J Dobrzanski, Kathleen A Rewers-Felkins, Khaliquzzaman A Samad, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2012
Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot studyStephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Immunological Investigations|July 27, 2010
Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients - a phase I/II studyStephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Immunological Investigations|October 29, 2009
Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II studyStephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Neuropsychiatric Disease and Treatment|August 8, 2019
Reduction in apathy following epilepsy surgeryLinda Mah, Joan Swearer, Catherine A Phillips, et al.
Immunopharmacology and Immunotoxicology|May 18, 2010
Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutionsStephen E Wright, Imelda S Quinlin, Kathleen A Rewers-Felkins, et al.
Immunological Investigations|June 15, 2007
MHC-restricted presentation of a single repeat of MUC1 mucinMelody K Orr, Janet S Burnside, Catherine A Phillips, et al.
Immunological Investigations|April 5, 2008
MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cellsStephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Clinical Immunology (Orlando, Fla.)|September 19, 2009
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survivalMark J Dobrzanski, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
International Journal of Molecular Medicine|March 14, 2002
Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cellsStephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Cancer Immunology, Immunotherapy : CII|November 16, 2011
Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancerMark J Dobrzanski, Kathleen A Rewers-Felkins, Khaliquzzaman A Samad, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2012
Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot studyStephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Immunological Investigations|July 27, 2010
Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients - a phase I/II studyStephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Immunological Investigations|October 29, 2009
Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II studyStephen E Wright, Kathleen A Rewers-Felkins, Imelda S Quinlin, et al.
Pageof 1